<DOC>
	<DOCNO>NCT00920140</DOCNO>
	<brief_summary>MEK111759 dose-escalation , Phase I/II , open-label study determine recommend dose regimen orally administer MEK inhibitor GSK1120212 subject relapse refractory leukemia . The recommend dose regimen select base safety , pharmacokinetic , pharmacodynamic profile . This study identify maximum tolerate recommend Phase II dose use dose-escalation procedure . Dose escalation continue base predefined parameter maximum tolerate dose establish . In Phase II , clinical efficacy GSK1120212 subject relapse refractory leukaemia ( AML , MDS CMML ) determine .</brief_summary>
	<brief_title>Open-label Study Evaluate Safety , PK , PD MEK Inhibitor GSK1120212 Subjects With Relapsed Refractory Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<criteria>Phase I Written informed consent provide . 18 year old old . Subjects must relapsed/refractory leukemias standard therapy anticipate result durable remission . Subjects poorrisk myelodysplasia ( MDS ) chronic melomonocytic leukemia ( CMML ) also eligible . Relapsed/refractory leukemias include acute nonlymphocytic leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia ( CML ) blast crisis . Subjects agnogenic myeloid metaplasia ( AMM ) also eligible . Subjects haematological malignancy associate human immunodeficiency virus ( HIV ) infection solid organ transplant NOT eligible . Subjects previously receive autologous stem cell transplant allow minimum three month elapse time transplant ( T0 ) subject recover transplantassociated toxicity prior first dose GSK1120212 . Subjects history allogeneic stem cell transplant eligible study participation provide follow eligibility criterion meet : transplant great 100 day prior study enrolment , subject take immunosuppressive medication ( per protocol ) least 1 month , sign symptom graft versus host disease Grade 1 skin involvement , active infection , subject meet remainder eligibility criterion outline protocol . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . Life expectancy least four week . Able swallow retain oral medication . Male subject must agree use one contraception method list protocol . Female subject must nonchildbearing potential list protocol use contraception method list protocol . Calcium Phosphate Product less equal 4.0 mmol ( square ) /L ( square ) 50mg ( square ) /dL ( square ) . Subjects must adequate organ function specify protocol . Phase II Confirmed diagnosis one following : Relapsed refractory acute myeloid leukemia ( AML ) , Secondary AML include AML arise antecedent hematologic disease ( e.g. , myelodysplastic syndrome , myeloproliferative disorder , therapyrelated AML ) , CMML , MDS . Cohorts 1 : RAS Positive AML/MDS Cohort 2 : Wild Type AML/MDS/CMML Cohort 3 : RAS Positive CMML Phase I Currently receive cancer therapy specify protocol . Received corticosteroid imatinib within 24h GSK1120212 administration . Received gemtuzumab ozogamicin ( myelotarg ) within two week GSK1120212 adminstration . Received investigational anticancer drug within four week five halflives , whichever short GSK1120212 administration , specify protocol . Received major surgery , radiotherapy , immunotherapy within four week GSK1120212 administration . Received chemotherapy regimens delay toxicity within last four week ( six week prior nitrosourea mitomycin C ) . Received chemotherapy regimen give continuously weekly basis limit potential delayed toxicity within last two week . Received MEK inhibitor . Current use prohibit medication per protocol . Current use warfarin . Low molecular weight heparin prophylactic lowdose warfarin permit per protocol . Presence active gastrointestinal disease condition interfere significantly absorption , distribution , metabolism , excretion drug . History RVO . Visible retinal pathology assess ophthalmologic exam consider risk factor retinal vein thrombosis . Intraocular pressure great 21mm Hg measure tonography . Psychological , familial , sociological , geographical condition permit compliance protocol . Condition investigator 's opinion would jeopardize compliance protocol . Symptomatic untreated central nervous system involvement hematologic malignancy , include primary CNS lymphoma . Subjects previously treat CNS involvement , asymptomatic without antiepileptic medication least two month eligible . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , cardiac disease ) . Unresolved toxicity great Grade 1 previous anticancer therapy except alopecia ( applicable ) unless agree GSK Medical Monitor investigator . QTc interval great 480 msec . History acute coronary syndrome ( include unstable angina ) , coronary angioplasty stenting within past 24 week . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , dimethyl sulfoxide ( DMSO ) , excipients ( See Section 3.10 ) . ( To date know FDA approve drug chemically relate GSK1120212 ) . Pregnant lactate female . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Oncology , GSK1120212 , MEK inhibitor , hematological malignancy , AML</keyword>
	<keyword>CMML</keyword>
	<keyword>MDS</keyword>
</DOC>